Acumen Pharmaceuticals (ABOS) Net Equity Issued and Repurchased (2021 - 2024)

Acumen Pharmaceuticals has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $7.9 million in Q1 2024.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $7.9 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $7.9 million (down 93.49% YoY) and the FY2024 annual result came in at $7.9 million, down 93.49% from the prior year.
• Net Equity Issued and Repurchased climbed to $7.9 million in Q1 2024 per ABOS's latest filing, from -$390000.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $138.5 million in Q3 2021 and troughed at -$390000.0 in Q4 2023.
• A 4-year average of $45.4 million and a median of $5.9 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased soared 126500.0% in 2022, then slumped 110.28% in 2023.
• Over 4 years, Net Equity Issued and Repurchased stood at -$3000.0 in 2021, then jumped by 126500.0% to $3.8 million in 2022, then tumbled by 110.28% to -$390000.0 in 2023, then surged by 2135.38% to $7.9 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $7.9 million, -$390000.0, and $122.3 million for Q1 2024, Q4 2023, and Q3 2023 respectively.